PDCD1 and pancreatic neoplasm: In detail, in the NCT03977272 clinical trial, 110 stage IV patients with pancreatic cancer are enrolling and the standard of care treatment, based on FOLFIRINOX (Folic acid, Irinotecan, Oxaliplatin, and 5-Fluorouracil), will be compared to the combination of FOLFIRINOX with an anti-PD-1 agent.